Abstract：Objective To explore the clinical effect of Ruxolitinib in the treatment of JAK2V617F-positive myeloproliterative neoplasms (MPN). Methods A total of 60 JAK2V617F positive MPN patients admitted to Ganzhou People′s Hospital from July 2017 to July 2019 were selected as the study subjects, and they were divided into observation group and control group by random number table method, with 30 patients in each group. The control group was treated with oral Hydroxycarbamide Tablets, while observation group was treated with oral Ruxolitinib. Total MPN-10 score,myelofibrosis (MF) grading assessment, spleen diameter, relative expression levels of JAK2V617F gene in bone marrow were compared between two groups before and after treatment, and the occurrence of adverse reactions between two groups during treatment was recorded. Results After treatment, the MPN-10 and MF scores of the observation group were lower than those of the control group, and the spleen diameter of the observation group was shorter than that of the control group,the differences were statistically significant (P＜0.05).The relative expression level of JAK2V617F gene in the observation group were lower than those in the control group after 6 months and 1 year of treatment, the differences were statistically significant (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). Conclusion Ruxolitinib can significantly reduce expression level of JAK2V617F gene in patients with JAK2V617F-positive MPN, reverse myelofibrosis level, and improve clinical curative effect.
邹民. 芦可替尼治疗JAK2V617F阳性骨髓增殖性肿瘤的临床效果[J]. 中国当代医药, 2022, 29(2): 79-81.
ZOU Min. Clinical effect of Ruxolitinib in the treatment of JAK2V617F-positive myeloproliferative neoplasms. 中国当代医药, 2022, 29(2): 79-81.
京公网安备 11010502046607号